Stock Watch: Vaccines, Oncology Frame Q4 Contrasts Between Pfizer And GSK
The Battle Of The RSV Vaccines Is Only Part Of The Story
While attempting to move beyond post-pandemic unfavorable revenue comparisons, other unfavorable comparisons emerged at Pfizer.
